ArticleOncotarget2016
Antigen-specific T cell Redirectors: a nanoparticle based approach for redirecting T cells.
Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 30 citations in OpenAlex.
- CD19-ReTARGCancers · 2025Article
- Metal-based nanoparticle in cancer treatment: lessons learned and challenges.Frontiers in bioengineering and biotechnology · 2024Review
- Nanomedicines in B cell-targeting therapies.Acta biomaterialia · 2022Review
- T cell receptor-targeted immunotherapeutics drive selective in vivo HIV- and CMV-specific T cell expansion in humanized mice.The Journal of clinical investigation · 2021Article
- Functional bionanomaterials for cell surface engineering in cancer immunotherapy.APL bioengineering · 2021Review
- CD8Cells · 2020Review
- Rapid Assembly and Screening of Multivalent Immune Cell-Redirecting Therapies for Leukemia.ACS combinatorial science · 2020Article
- Metal Oxide Nanoparticles as Biomedical Materials.Biomimetics (Basel, Switzerland) · 2020Review
- T cell immunotherapy enhanced by designer biomaterials.Biomaterials · 2019Review
- Applications of molecular engineering in T-cell-based immunotherapies.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2019Review
- Biomimetic Nanoparticle Vaccines for Cancer Therapy.Advanced biosystems · 2019Article
- Recent advances and challenges of repurposing nanoparticle-based drug delivery systems to enhance cancer immunotherapy.Theranostics · 2019Review
- Polymeric micro- and nanoparticles for immune modulation.Biomaterials science · 2018Review
- Soluble MHC class I complexes for targeted immunotherapy.Life sciences · 2018Review
- Engineering Platforms for T Cell Modulation.International review of cell and molecular biology · 2018Review
- Delivering safer immunotherapies for cancer.Advanced drug delivery reviews · 2017Review
- Metallic Nanoparticles for Cancer Immunotherapy.Materials today (Kidlington, England)Article
Corrections and comments
- Erratum issued
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
Abstract
Redirection of T cells to target and destroy tumors has become an important clinical tool and major area of research in tumor immunology. Here we present a novel, nanoparticle-based approach to selectively bind antigen-specific cytotoxic T cells (CTL) and redirect them to kill tumors, termed ATR (Antigen-specific T cell Redirectors). ATR were generated by decorating nanoparticles with both an antigen-specific T cell binding moiety, either peptide loaded MHC-Ig dimer or clonotypic anti-TCR antibody, and a model tumor cell binding moiety, anti-CD19 antibody to engage CD19+ tumor cells. ATR stably bind tumor cells and CTL in a dose dependent fashion and stimulate antigen-specific conjugate formation between those cells. ATR induced redirected lysis of tumor cells in vitro, as demonstrated by 51Cr-release killing. In vivo ATR administration led to reduced tumor growth in a SCID/beige human lymphoma treatment model. In summary, ATR represent a novel, nanoparticle based approach for redirecting antigen-specific CTL to kill tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.